thiotepa has been researched along with Graft-Versus-Host Disease in 72 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-four children with beta-thalassemia major received abatacept at a dose of 10 mg/kg intravenously on days -1, +5, +14, and +28 after HSCT in addition to calcineurin inhibitors and methylprednisolone." | 8.02 | Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. ( Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L, 2021) |
| "In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results." | 7.96 | Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. ( Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G, 2020) |
| " Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and antithymocyte globulin (ATG)." | 7.70 | Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. ( Bacigalupo, A; Barbanti, M; Berisso, G; Bregante, S; Bruno, B; Casarino, L; Di Grazia, C; Dominietto, A; Ficai, G; Ghinatti, C; Gualandi, F; Lamparelli, T; Raiola, AM; Sacchi, N; Sessarego, M; van Lint, MT; Verdiani, S, 2000) |
| "All but four had advanced hematologic malignancies." | 6.71 | Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. ( Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M, 2003) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and mycophenolate for all patients, associated with ATG in 39 patients (76." | 5.30 | Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. ( Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A, 2019) |
| "Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), fludarabine (n = 15)." | 5.17 | Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. ( Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R, 2013) |
| " This study reports the results of UD-CBT in 22 adults with hematologic malignancies following conditioning with thiotepa, busulfan, cyclophosphamide, and antithymocyte globulin in 21, with thiotepa, fludarabine, and antithymocyte globulin in 1, and graft-versus-host disease (GVHD) prophylaxis with cyclosporine and prednisone." | 5.09 | Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. ( Andreu, R; Barragán, E; Benlloch, L; Bolufer, P; Cervera, J; de La Rubia, J; García, I; Jarque, I; Jiménez, C; Larrea, L; Martín, G; Martínez, J; Marty, ML; Mollá, S; Moscardó, F; Planelles, D; Plumé, G; Regadera, AI; Saavedra, S; Sanz, GF; Sanz, MA; Senent, L; Soler, MA; Solves, P, 2001) |
| "Twenty-four children with beta-thalassemia major received abatacept at a dose of 10 mg/kg intravenously on days -1, +5, +14, and +28 after HSCT in addition to calcineurin inhibitors and methylprednisolone." | 4.02 | Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. ( Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L, 2021) |
| "One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis." | 4.02 | Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. ( Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A, 2021) |
| "In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results." | 3.96 | Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. ( Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G, 2020) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine A and alemtuzumab (10-20 mg)." | 3.78 | Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity. ( Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R, 2012) |
| " In order to decrease nonrelapse mortality, and enhance the graft-versus-tumor effect, a program was designed in which a reduced conditioning with thiotepa, fludarabine, and cyclophosphamide was associated with programmed reinfusions of donor lymphocytes for patients without graft-versus-host disease (GVHD), not achieving clinical and molecular remission after transplantation." | 3.71 | Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. ( Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F, 2002) |
| " Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and antithymocyte globulin (ATG)." | 3.70 | Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. ( Bacigalupo, A; Barbanti, M; Berisso, G; Bregante, S; Bruno, B; Casarino, L; Di Grazia, C; Dominietto, A; Ficai, G; Ghinatti, C; Gualandi, F; Lamparelli, T; Raiola, AM; Sacchi, N; Sessarego, M; van Lint, MT; Verdiani, S, 2000) |
| "Forty-seven patients with advanced hematologic malignancies with a median age of 23 years (30 adults and 17 children) were treated." | 2.77 | Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. ( Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL, 2012) |
| " This treosulfan-based preparation proved to be safe and effective for thalassemia patients given allogeneic HSCT." | 2.77 | Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. ( Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M, 2012) |
| "Diagnoses were AML (n=18), ALL (n=3), multiple myeloma (n=11), lymphoma (n=16) and CML (n=1)." | 2.73 | A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. ( Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A, 2008) |
| "All but four had advanced hematologic malignancies." | 2.71 | Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. ( Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M, 2003) |
| "Thiotepa has excellent antileukemic and immunosuppressive activity, and could therefore be a useful drug in the conditioning regimen for patients with advanced hematologic neoplasms." | 2.71 | Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. ( Beall, CL; Bunner, P; Devetten, MP; Ericson, SG; Lynch, JP; Qazilbash, MH; Weisenborn, R, 2004) |
| "Renal cell carcinoma has been shown to be responsive to immunotherapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy." | 2.41 | Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. ( Abonour, R; Logan, TF; Nelson, RP, 2002) |
| "For acute lymphoblastic leukemia (ALL) patients, total body irradiation (TBI)- based conditioning regimens are the first choice specially in young population." | 1.91 | Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. ( Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z, 2023) |
| "All patients had high-risk hematologic malignancies, were younger than 20 years, and were in complete cytological remission at the time of allo-HSCT." | 1.91 | Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. ( Andersson, BS; Anurathapan, U; Hongeng, S; Pakakasama, S; Pongpitcha, P; Sirachainan, N; Songdej, D; Tannumsaeung, S, 2023) |
| "Optimal conditioning for adults with acute lymphoblastic leukemia (ALL) treated with haploidentical hematopoietic cell transplantation (haplo-HCT) and post-transplant cyclophosphamide has not been established so far." | 1.72 | Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W ( Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A, 2022) |
| "We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion." | 1.62 | Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. ( Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I, 2021) |
| "Busulfan was administered IV and according to body weight." | 1.62 | Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. ( Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S, 2021) |
| "Thiotepa is an alkylating compound with an antineoplastic and myeloablative activity and can mimic the effect of radiation." | 1.43 | Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the Euro ( Arcese, W; Bacigalupo, A; Beelen, D; Cornelissen, J; de Rosa, G; Eder, S; Kuball, J; Labopin, M; Majolino, I; Mohty, M; Nagler, A; Or, R; Schaap, NP; Veelken, H; Volin, L, 2016) |
| "For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice." | 1.40 | Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome. ( Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C, 2014) |
| "Thirty-one consecutive patients with acute myelogenous leukemia (AML) in first complete remission and 8 with AML in second complete remission received T cell-depleted allogeneic bone marrow transplants from HLA-identical sibling donors." | 1.30 | T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. ( Black, PM; Bleau, SA; Boulad, F; Carabasi, MH; Castro-Malaspina, H; Childs, BH; Collins, NH; Gillio, AP; Heller, G; Kernan, NA; Mackinnon, S; O'Reilly, RJ; Papadopoulos, EB; Small, TN; Szabolcs, P; Taylor, J; Yahalom, J; Young, JW, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.39) | 18.7374 |
| 1990's | 13 (18.06) | 18.2507 |
| 2000's | 13 (18.06) | 29.6817 |
| 2010's | 22 (30.56) | 24.3611 |
| 2020's | 23 (31.94) | 2.80 |
| Authors | Studies |
|---|---|
| Swoboda, R | 1 |
| Labopin, M | 8 |
| Giebel, S | 2 |
| Angelucci, E | 6 |
| Arat, M | 1 |
| Aljurf, M | 3 |
| Sica, S | 3 |
| Pavlu, J | 1 |
| Socié, G | 4 |
| Bernasconi, P | 2 |
| Rigacci, L | 1 |
| Tischer, J | 1 |
| Risitano, A | 1 |
| Rovira, M | 1 |
| Saccardi, R | 1 |
| Pioltelli, P | 3 |
| Van Gorkom, G | 1 |
| Vitek, A | 1 |
| Savani, BN | 2 |
| Spyridonidis, A | 3 |
| Peric, Z | 2 |
| Nagler, A | 10 |
| Mohty, M | 11 |
| Bonifazi, F | 3 |
| Pavoni, C | 1 |
| Peccatori, J | 1 |
| Giglio, F | 1 |
| Arpinati, M | 1 |
| Busca, A | 1 |
| Grassi, A | 1 |
| Iori, AP | 3 |
| Patriarca, F | 2 |
| Brunello, L | 1 |
| Di Grazia, C | 4 |
| Carella, AM | 1 |
| Cilloni, D | 1 |
| Picardi, A | 2 |
| Proia, A | 1 |
| Santarone, S | 4 |
| Sorasio, R | 1 |
| Carluccio, P | 1 |
| Chiusolo, P | 4 |
| Cupri, A | 1 |
| Luppi, M | 1 |
| Nozzoli, C | 1 |
| Baronciani, D | 2 |
| Casini, M | 1 |
| Grillo, G | 1 |
| Musso, M | 1 |
| Onida, F | 2 |
| Palazzo, G | 1 |
| Parma, M | 1 |
| Tringali, S | 1 |
| Vacca, A | 3 |
| Vallisa, D | 1 |
| Sacchi, N | 2 |
| Oldani, E | 1 |
| Masciulli, A | 1 |
| Gheorghiu, A | 1 |
| Girmenia, C | 1 |
| Martino, M | 1 |
| Bruno, B | 4 |
| Rambaldi, A | 5 |
| Ciceri, F | 2 |
| Mehta, P | 1 |
| Kapoor, J | 1 |
| Singh, A | 1 |
| Yadav, N | 1 |
| Singh, R | 1 |
| Halder, R | 1 |
| Verma, M | 1 |
| Agrawal, N | 1 |
| Ahmed, R | 1 |
| Bhurani, D | 1 |
| Banet, A | 3 |
| Bazarbachi, A | 2 |
| Stocker, N | 1 |
| Duléry, R | 4 |
| Malard, F | 4 |
| Van de Wyngaert, Z | 2 |
| Genthon, A | 1 |
| Memoli, M | 2 |
| Legrand, O | 4 |
| Bonnin, A | 3 |
| Ledraa, T | 4 |
| Belhocine, R | 4 |
| Sestili, S | 4 |
| El-Cheikh, J | 1 |
| Brissot, E | 4 |
| Luo, C | 1 |
| Wu, G | 1 |
| Huang, X | 1 |
| Ding, Y | 1 |
| Huang, Y | 1 |
| Song, Q | 1 |
| Hou, Y | 1 |
| Chen, J | 2 |
| Li, X | 1 |
| Xu, S | 1 |
| Kharya, G | 5 |
| Sapkota, S | 3 |
| Teotia, N | 3 |
| Chaudhary, M | 3 |
| Swathymon, KK | 3 |
| Chodan, P | 3 |
| Peters, S | 3 |
| Anthony, A | 3 |
| Sharma, B | 4 |
| Yadav, H | 3 |
| Bakane, A | 4 |
| Joseph, M | 3 |
| Halahleh, KA | 3 |
| Ma'koseh, M | 3 |
| Sultan, I | 3 |
| Rimawi, DH | 3 |
| Muradi, I | 3 |
| Gale, RP | 3 |
| Tannumsaeung, S | 3 |
| Anurathapan, U | 3 |
| Pakakasama, S | 3 |
| Pongpitcha, P | 3 |
| Songdej, D | 3 |
| Sirachainan, N | 3 |
| Andersson, BS | 4 |
| Hongeng, S | 3 |
| Jaiswal, SR | 1 |
| Bhat, S | 1 |
| Raj, R | 1 |
| Yadav, SP | 1 |
| Dua, V | 1 |
| Sen, S | 1 |
| Badiger, S | 1 |
| Uppuluri, R | 1 |
| Rastogi, N | 1 |
| Sachdev, M | 1 |
| Saifullah, A | 1 |
| Chakrabarti, S | 1 |
| Cassanello, G | 1 |
| Serpenti, F | 1 |
| Bagnoli, F | 1 |
| Saporiti, G | 1 |
| Goldaniga, M | 1 |
| Cavallaro, F | 1 |
| Barbullushi, K | 1 |
| Bellani, V | 1 |
| Galassi, G | 1 |
| Shouval, R | 1 |
| Vega, Y | 1 |
| Fein, JA | 1 |
| Danylesko, I | 1 |
| Shem Tov, N | 1 |
| Yerushalmi, R | 1 |
| Sobas, M | 1 |
| Czyż, A | 1 |
| Shimoni, A | 1 |
| Bhatt, ST | 1 |
| Schulz, G | 1 |
| Hente, M | 1 |
| Slater, A | 1 |
| Murray, L | 2 |
| Shenoy, S | 3 |
| Bednarski, JJ | 1 |
| Mohty, R | 1 |
| Bastos, J | 2 |
| Battipaglia, G | 4 |
| Giannotti, F | 2 |
| Vekhoff, A | 3 |
| Lapusan, S | 3 |
| Isnard, F | 2 |
| Mediavilla, C | 3 |
| Rubio, MT | 3 |
| Ruggeri, A | 2 |
| Sora, F | 2 |
| Grazia, CD | 1 |
| Raiola, AM | 5 |
| Bregante, S | 6 |
| Mordini, N | 2 |
| Olivieri, A | 3 |
| Grisariu, S | 2 |
| Terruzzi, E | 1 |
| Bacigalupo, A | 7 |
| Khandelwal, P | 1 |
| Yeh, RF | 1 |
| Yu, L | 1 |
| Lane, A | 1 |
| Dandoy, CE | 1 |
| El-Bietar, J | 1 |
| Davies, SM | 1 |
| Grimley, MS | 1 |
| Fox, ML | 2 |
| García-Cadenas, I | 2 |
| Pérez, AM | 1 |
| Villacampa, G | 1 |
| Piñana, JL | 2 |
| Ortí, G | 1 |
| Montoro, J | 1 |
| Roldán, E | 1 |
| Bosch Vilaseca, A | 1 |
| Martino, R | 3 |
| Salamero, O | 1 |
| Saavedra, S | 2 |
| Hernandez-Boluda, JC | 2 |
| Esquirol, A | 3 |
| Sierra, J | 3 |
| Sanz, J | 3 |
| Solano, C | 3 |
| Bosch, F | 1 |
| Barba, P | 2 |
| Valcarcel, D | 1 |
| Paviglianiti, A | 2 |
| Bianchessi, A | 1 |
| Hirsch, P | 1 |
| Favale, F | 1 |
| Boussaroque, A | 1 |
| Blaise, D | 3 |
| Forcade, E | 1 |
| Berceanu, A | 1 |
| Bulabois, CE | 1 |
| Kröger, N | 2 |
| Ceballos, P | 1 |
| Mielke, S | 1 |
| El Cheikh, J | 1 |
| Yakoub-Agha, I | 3 |
| Savani, B | 1 |
| Giammarco, S | 1 |
| Gualandi, F | 5 |
| Varaldo, R | 2 |
| Laurenti, L | 1 |
| Metafuni, E | 1 |
| Innocenti, I | 1 |
| Autore, F | 1 |
| Murgia, B | 1 |
| Mauff, K | 1 |
| Wendel, L | 1 |
| Arcese, W | 5 |
| Fanin, R | 1 |
| Chalandon, Y | 1 |
| Marotta, G | 1 |
| Sever, M | 1 |
| Contentin, N | 1 |
| de Wreede, LC | 1 |
| Czerw, T | 1 |
| Hayden, P | 1 |
| McLornan, D | 1 |
| Yalcin, K | 1 |
| Pehlivan, B | 1 |
| Celen, S | 1 |
| Bas, EG | 1 |
| Kabakci, C | 1 |
| Pashayev, D | 1 |
| Daloglu, H | 1 |
| Zhumatayev, S | 1 |
| Uygun, V | 1 |
| Karasu, GT | 1 |
| Hazar, V | 1 |
| Yesilipek, A | 1 |
| Pascual, MJ | 1 |
| Herruzo, B | 1 |
| Ferrà, C | 1 |
| Pérez, A | 1 |
| Torio, A | 1 |
| Torrent, A | 1 |
| Cuesta, M | 1 |
| Marsh, RA | 1 |
| Hebert, K | 1 |
| Kim, S | 1 |
| Dvorak, CC | 1 |
| Aquino, VM | 1 |
| Baker, KS | 1 |
| Chellapandian, D | 1 |
| Dávila Saldaña, B | 1 |
| Duncan, CN | 1 |
| Eckrich, MJ | 1 |
| Georges, GE | 1 |
| Olson, TS | 1 |
| Pulsipher, MA | 2 |
| Stenger, E | 1 |
| Lugt, MV | 1 |
| Yu, LC | 1 |
| Gennery, AR | 1 |
| Eapen, M | 1 |
| Abraham, A | 1 |
| Cluster, A | 1 |
| Jacobsohn, D | 1 |
| Delgado, D | 1 |
| Hulbert, ML | 1 |
| Kukadiya, D | 1 |
| Saraceni, F | 1 |
| Beohou, E | 2 |
| Stepensky, P | 1 |
| Passweg, J | 2 |
| Lanza, F | 1 |
| Sheth, V | 1 |
| Nachmias, B | 1 |
| Avni, B | 1 |
| Or, R | 5 |
| Shapira, M | 1 |
| Esiashvili, N | 1 |
| Lu, X | 1 |
| Ulin, K | 1 |
| Laurie, F | 1 |
| Kessel, S | 1 |
| Kalapurakal, JA | 1 |
| Merchant, TE | 1 |
| Followill, DS | 1 |
| Sathiaseelan, V | 1 |
| Schmitter, MK | 1 |
| Devidas, M | 1 |
| Chen, Y | 1 |
| Wall, DA | 1 |
| Brown, PA | 1 |
| Hunger, SP | 1 |
| Grupp, SA | 1 |
| de Wyngaert, ZV | 1 |
| Adaeva, R | 1 |
| Pagliardini, T | 1 |
| Castagna, L | 1 |
| Harbi, S | 1 |
| Porta, MD | 1 |
| Rey, J | 1 |
| Fürst, S | 1 |
| Bramanti, S | 1 |
| Saillard, C | 1 |
| Legrand, F | 1 |
| Maisano, V | 1 |
| Faucher, C | 1 |
| Granata, A | 1 |
| Hospital, MA | 1 |
| Lining, W | 1 |
| Weiller, PJ | 1 |
| Calmels, B | 1 |
| Charbonnier, A | 1 |
| Lemarie, C | 1 |
| Chabannon, C | 1 |
| Vey, N | 1 |
| Mokart, D | 1 |
| Devillier, R | 1 |
| Bayraktar, UD | 1 |
| de Lima, M | 2 |
| Saliba, RM | 2 |
| Maloy, M | 1 |
| Castro-Malaspina, HR | 1 |
| Rondon, G | 2 |
| Chiattone, A | 1 |
| Jakubowski, AA | 1 |
| Boulad, F | 2 |
| Kernan, NA | 2 |
| O'Reilly, RJ | 2 |
| Champlin, RE | 2 |
| Giralt, S | 3 |
| Papadopoulos, EB | 2 |
| Schwinger, W | 1 |
| Sovinz, P | 1 |
| Benesch, M | 1 |
| Lackner, H | 1 |
| Seidel, M | 1 |
| Strenger, V | 1 |
| Sperl, D | 1 |
| Raicht, A | 1 |
| Brunner-Krainz, M | 1 |
| Paschke, E | 1 |
| Plecko, B | 1 |
| Urban, C | 1 |
| Depau, C | 1 |
| Targhetta, C | 1 |
| Derudas, D | 1 |
| Culurgioni, F | 1 |
| Tandurella, I | 1 |
| Latte, G | 1 |
| Palmas, A | 1 |
| Eder, S | 3 |
| Majolino, I | 1 |
| de Rosa, G | 1 |
| Volin, L | 1 |
| Beelen, D | 1 |
| Veelken, H | 1 |
| Schaap, NP | 1 |
| Kuball, J | 1 |
| Cornelissen, J | 1 |
| Parody, R | 1 |
| Gayoso, J | 1 |
| Montesinos, P | 1 |
| Guidi, S | 1 |
| Terol, MJ | 1 |
| Moscardó, F | 2 |
| Sanz, MA | 2 |
| Sanz, G | 1 |
| Finke, J | 5 |
| Bunjes, D | 1 |
| Kanz, L | 1 |
| Messina, G | 1 |
| Bernardo, ME | 2 |
| Zecca, M | 3 |
| Piras, E | 2 |
| Giorgiani, G | 3 |
| Cugno, C | 1 |
| Caocci, G | 2 |
| Comoli, P | 1 |
| Mastronuzzi, A | 2 |
| Merli, P | 1 |
| La Nasa, G | 2 |
| Locatelli, F | 4 |
| Cluzeau, T | 1 |
| De Matteis, M | 1 |
| Mounier, N | 1 |
| Mannone, L | 1 |
| Gratecos, N | 1 |
| Ticchioni, M | 1 |
| Thyss, A | 1 |
| Raynaud, S | 1 |
| Cassuto, JP | 1 |
| Sirvent, A | 1 |
| Ciurea, SO | 1 |
| Hamerschlak, N | 1 |
| Karduss Aurueta, AJ | 1 |
| Bassett, R | 1 |
| Fernandez-Vina, M | 1 |
| Petropoulos, D | 2 |
| Worth, LL | 1 |
| Chan, KW | 1 |
| Couriel, DR | 1 |
| Sharma, M | 1 |
| Qazilbash, M | 1 |
| Jones, RB | 1 |
| Kebriaei, P | 1 |
| McMannis, J | 1 |
| Hosing, CM | 1 |
| Nieto, Y | 1 |
| Shpall, EJ | 1 |
| Weisdorf, D | 1 |
| Cooley, S | 1 |
| Devine, S | 2 |
| Fehniger, TA | 1 |
| DiPersio, J | 1 |
| Anasetti, C | 1 |
| Waller, EK | 1 |
| Porter, D | 1 |
| Farag, S | 1 |
| Drobyski, W | 1 |
| Defor, T | 1 |
| Haagenson, M | 1 |
| Curtsinger, J | 1 |
| Miller, J | 1 |
| Christopoulos, P | 2 |
| Bertz, H | 3 |
| Ihorst, G | 1 |
| Marks, R | 2 |
| Wäsch, R | 2 |
| Bertaina, A | 1 |
| Pagliara, D | 1 |
| Contoli, B | 1 |
| Pinto, RM | 1 |
| Dominietto, A | 2 |
| Ghiso, A | 1 |
| Lamparelli, T | 4 |
| Van Lint, MT | 4 |
| Geroldi, S | 1 |
| Luchetti, S | 1 |
| Ballerini, F | 1 |
| Miglino, M | 1 |
| Choudhary, D | 1 |
| Sharma, SK | 1 |
| Gupta, N | 1 |
| Pavecha, P | 1 |
| Handoo, A | 1 |
| Setia, R | 1 |
| Katewa, S | 1 |
| Larsen, JT | 1 |
| Hogan, WJ | 1 |
| Micallef, IN | 1 |
| Dispenzieri, A | 1 |
| Gertz, MA | 1 |
| Inwards, DJ | 1 |
| Tun, HW | 1 |
| Roy, V | 1 |
| Geyer, SM | 1 |
| Allred, JB | 1 |
| Wu, W | 1 |
| Ansell, SM | 1 |
| Elliott, MA | 1 |
| Tefferi, A | 1 |
| Porrata, LF | 1 |
| Gastineau, DA | 1 |
| Lacy, MQ | 1 |
| Litzow, MR | 1 |
| Schmoor, C | 1 |
| Waterhouse, M | 1 |
| Nelson, RP | 1 |
| Logan, TF | 1 |
| Abonour, R | 1 |
| van Besien, K | 2 |
| Wickrema, A | 1 |
| Jessop, E | 1 |
| Amin, K | 2 |
| Yassine, M | 1 |
| Maynard, V | 1 |
| Stock, W | 1 |
| Peace, D | 1 |
| Ravandi, F | 1 |
| Chen, YH | 1 |
| Cheung, T | 1 |
| Vijayakumar, S | 1 |
| Hoffman, R | 1 |
| Sosman, J | 1 |
| Fujimaki, K | 1 |
| Taguchi, J | 1 |
| Fujita, H | 1 |
| Hattori, M | 1 |
| Yamazaki, E | 1 |
| Takahashi, N | 1 |
| Fujisawa, S | 1 |
| Kanamori, H | 1 |
| Maruta, A | 1 |
| Ishigatsubo, Y | 1 |
| Devetten, MP | 1 |
| Qazilbash, MH | 1 |
| Beall, CL | 1 |
| Bunner, P | 1 |
| Weisenborn, R | 1 |
| Lynch, JP | 1 |
| Ericson, SG | 1 |
| Bunin, N | 1 |
| Aplenc, R | 1 |
| Grupp, S | 1 |
| Pierson, G | 1 |
| Monos, D | 1 |
| Grüllich, C | 1 |
| Müller, CI | 1 |
| Przepiorka, D | 3 |
| Ippoliti, C | 1 |
| van Beisen, K | 1 |
| Mehra, R | 2 |
| Deisseroth, AB | 1 |
| Andersson, B | 2 |
| Luna, M | 1 |
| Cork, A | 1 |
| Lee, M | 1 |
| Martelli, MF | 2 |
| Aversa, F | 2 |
| Tricot, G | 2 |
| Vesole, DH | 1 |
| Jagannath, S | 1 |
| Hilton, J | 1 |
| Munshi, N | 1 |
| Barlogie, B | 1 |
| Valbonesi, M | 1 |
| Lercari, G | 1 |
| Carlier, P | 1 |
| Occhini, D | 1 |
| Valeriani, A | 1 |
| Piaggio, G | 1 |
| Pitto, A | 2 |
| Benvenuto, F | 1 |
| Figari, O | 1 |
| De Stefano, G | 1 |
| Caimo, A | 1 |
| Sessarego, M | 3 |
| Thall, P | 1 |
| Korbling, M | 1 |
| Pugh, WC | 1 |
| Khouri, I | 1 |
| Anderlini, P | 1 |
| Mirza, N | 1 |
| Seong, D | 1 |
| Gajewski, J | 1 |
| Hester, J | 1 |
| Cabanillas, F | 1 |
| Champlin, R | 1 |
| Carabasi, MH | 1 |
| Castro-Malaspina, H | 1 |
| Childs, BH | 1 |
| Mackinnon, S | 1 |
| Gillio, AP | 1 |
| Small, TN | 1 |
| Szabolcs, P | 1 |
| Taylor, J | 1 |
| Yahalom, J | 1 |
| Collins, NH | 1 |
| Bleau, SA | 1 |
| Black, PM | 1 |
| Heller, G | 1 |
| Young, JW | 1 |
| Miniero, R | 1 |
| Rocha, V | 1 |
| Saracco, P | 1 |
| Brichard, B | 1 |
| Roberts, I | 1 |
| Yaniv, I | 1 |
| Beksac, M | 1 |
| Bernaudin, F | 1 |
| Gluckman, E | 1 |
| Rosales, F | 2 |
| Peylan-Ramu, N | 1 |
| Cividalli, G | 1 |
| Varadi, G | 2 |
| Naparstek, E | 2 |
| Slavin, S | 2 |
| Worth, L | 1 |
| Tran, H | 1 |
| Culbert, S | 1 |
| Mullen, C | 1 |
| Roberts, W | 1 |
| Chan, K | 1 |
| Pession, A | 1 |
| Messina, C | 1 |
| Bonetti, F | 1 |
| Favre, C | 1 |
| Prete, A | 1 |
| Cesaro, S | 1 |
| Porta, F | 1 |
| Mazzarino, I | 1 |
| Rondelli, R | 1 |
| Appelbaum, FR | 1 |
| Berisso, G | 2 |
| Frassoni, F | 1 |
| Fugazza, G | 1 |
| Di Stefano, F | 1 |
| van der Wall, E | 1 |
| Horn, T | 1 |
| Bright, E | 1 |
| Passos-Coehlo, JL | 1 |
| Bond, S | 1 |
| Clarke, B | 1 |
| Altomonte, V | 1 |
| McIntyre, K | 1 |
| Vogelsang, G | 1 |
| Noga, SJ | 1 |
| Davis, JM | 1 |
| Thomassen, J | 1 |
| Ohly, KV | 1 |
| Lee, SM | 1 |
| Fetting, J | 1 |
| Armstrong, DK | 1 |
| Davidson, NE | 1 |
| Hess, AD | 1 |
| Kennedy, MJ | 1 |
| Barbanti, M | 1 |
| Ficai, G | 1 |
| Ghinatti, C | 1 |
| Casarino, L | 1 |
| Verdiani, S | 1 |
| Sanz, GF | 1 |
| Planelles, D | 1 |
| Senent, L | 1 |
| Cervera, J | 1 |
| Barragán, E | 1 |
| Jiménez, C | 1 |
| Larrea, L | 1 |
| Martín, G | 1 |
| Martínez, J | 1 |
| Jarque, I | 1 |
| Plumé, G | 1 |
| Andreu, R | 1 |
| Regadera, AI | 1 |
| García, I | 1 |
| Mollá, S | 1 |
| Solves, P | 1 |
| de La Rubia, J | 1 |
| Bolufer, P | 1 |
| Benlloch, L | 1 |
| Soler, MA | 1 |
| Marty, ML | 1 |
| Corradini, P | 1 |
| Tarella, C | 1 |
| Gianni, AM | 1 |
| Voena, C | 1 |
| Zallio, F | 1 |
| Ladetto, M | 1 |
| Falda, M | 1 |
| Lucesole, M | 1 |
| Dodero, A | 1 |
| Benedetti, F | 1 |
| Sajeva, MR | 1 |
| Tresoldi, M | 1 |
| Pileri, A | 1 |
| Bordignon, C | 1 |
| Bregni, M | 1 |
| Subrahmanyan, TP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime[NCT01821781] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | ||
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies[NCT01810926] | Phase 2 | 130 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
| Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease[NCT03240731] | Phase 2 | 18 participants (Anticipated) | Interventional | 2017-08-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 63.2 |
4 reviews available for thiotepa and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
Topics: Adult; Bayes Theorem; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Tra | 2023 |
Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; C | 2002 |
Is there a best transplant conditioning regimen for acute myeloid leukemia?
Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 2000 |
Graft versus host disease prophylaxis today.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transplantation; Cyclophosphamide | 1991 |
28 trials available for thiotepa and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospect | 2022 |
A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.
Topics: Alemtuzumab; Child; Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Granulomatous Diseas | 2020 |
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem C | 2017 |
Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group.
Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; | 2019 |
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Diseas | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; | 2019 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Fema | 2016 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transpla | 2016 |
Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Disease-Free Survival; Female; Graft vs Host Disease; Humans; L | 2017 |
Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Disease-Free Survival; Female; Graft vs | 2017 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; F | 2008 |
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood | 2012 |
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Ethnicity | 2012 |
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graf | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan | 2013 |
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Gra | 2013 |
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Graft Surviv | 2003 |
Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Graft vs | 2004 |
Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias.
Topics: Adolescent; Adult; Antigens, CD34; CD3 Complex; Child; Child, Preschool; Chronic Disease; Cyclophosp | 2006 |
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2008 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1994 |
Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone M | 1996 |
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Drug Therapy, | 1997 |
Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord.
Topics: Anemia, Sickle Cell; Antineoplastic Agents, Alkylating; beta-Thalassemia; Child; Child, Preschool; C | 1998 |
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 1999 |
Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chil | 1999 |
Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 2000 |
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Femal | 2001 |
40 other studies available for thiotepa and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, M | 2022 |
Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft vs Host | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Impact of Conditioning Regimen and Graft-versus-Host Disease Prophylaxis on The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation for High-Risk Severe Aplastic Anemia in Children and Young Adults: A Report from the Pediatric Severe Apla
Topics: Abatacept; Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Humans; Peripheral Bloo | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibro | 2020 |
Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
Topics: Antilymphocyte Serum; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic | 2020 |
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2020 |
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; | 2021 |
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Human | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middl | 2021 |
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2021 |
Second haploidentical stem cell transplantation for primary graft failure.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neopl | 2021 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 2021 |
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2021 |
Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2022 |
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 2018 |
Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.
Topics: Adolescent; Adult; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2019 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 2013 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Si | 2014 |
Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the Euro
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematopoiet | 2016 |
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2011 |
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyc | 2012 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host | 2013 |
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Mal | 2013 |
Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined M | 2004 |
Is there any future for T-cell depleted bone marrow transplantation in chronic myeloid leukaemia?
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Female; G | 1993 |
Graft-versus-myeloma effect: proof of principle.
Topics: Adult; Bone Marrow Transplantation; CD3 Complex; Cyclophosphamide; Disease Progression; Female; Graf | 1996 |
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Purging; Bone Marrow Transplantati | 1998 |
The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclo | 1999 |
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Combined Mo | 1999 |
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Topics: Adult; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Administration Schedule; Female; Fo | 2000 |
Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
Topics: Actuarial Analysis; Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Pr | 2000 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graf | 2002 |
T-cell depletion in unrelated bone marrow transplantation.
Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Cell Separation | 1992 |
Effect of neonatal thymectomy and thiotepa on the susceptibility of mice to the lethal effects of poxviruses.
Topics: Aging; Animals; Antibody Formation; Antigen-Antibody Reactions; Chloramphenicol; Ectromelia virus; G | 1968 |